Hong Lei, MD
Neurology · Tucson, AZNPI 1487780284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,235 of the $21,479 with a category attached, or 89.6%. Teva Pharmaceuticals USA, Inc. accounts for 93.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $9,795 and has fallen 97.1% since, to $286 in 2025.
Across 74 payments — averaging $290.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$20K
- Abbott$627
- AbbVie$372
- Novartis$134
- Neurocrine Biosciences, Inc.$74
- Takeda Pharmaceuticals U.S.A., Inc.$60
- plus $167 from 8 others
Across 41 payments — averaging $1393.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$57K
What the payments were for
- Speaking & faculty fees$19,23590%
- Travel & lodging$2131%
- Food & beverage$1,9199%
- Education$1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $20,045 |
| Abbott | 24 | $627 |
| AbbVie(2 entities) | 19 | $372 |
| Novartis | 2 | $134 |
| Neurocrine Biosciences, Inc. | 1 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $60 |
| Noctrix Health, Inc. | 2 | $57 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| MDD US Operations, LLC | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Amgen | 1 | $18 |
| Biogen | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$12,963
- Austedo XR$6,745
- INFINITY$297
- KESIMPTA$119
How this compares
$21,479 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $107,346 |
| NeuproRotigotine | 34 | $47,599 |
| InbrijaLevodopa | 11 | $40,351 |
| RytaryCarbidopa/Levodopa | 15 | $25,271 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 196 | $9,122 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 60 | $5,525 |
| AmantadineAmantadine Hcl | 77 | $4,676 |
| Tetrabenazine | 23 | $4,232 |
| Baclofen | 84 | $3,520 |
| Ropinirole Hcl | 55 | $2,586 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 14 | $2,120 |
| Primidone | 54 | $2,112 |
| Rasagiline Mesylate | 22 | $1,924 |
| Gabapentin | 51 | $1,387 |
| Propranolol Hcl ErPropranolol Hcl | 21 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $20,045 | $107,34619 claims |
| Amneal Pharmaceuticals LLCRytary | $15 | $25,27115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.
Other neurology in Tucson
- Francisco ValdiviaTucson$137K
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.